For over three decades Nagy has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. Nagy is a founder and was the Head of R&D of MiNA Therapeutics. Whilst at MiNA he was driving the development of an saRNA drug (a new class of medicines) which is currently being trialled in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, ClinicalTrials.gov ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan. He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Currently he is the CEO of Apterna Limited, a company focussed on novel oligonucleotide deliver. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018).
